These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38793610)

  • 1. The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.
    Martin J; Chen X; Jia X; Shao Q; Liu B
    Viruses; 2024 May; 16(5):. PubMed ID: 38793610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term passage of Vif-null HIV-1 in CD4
    Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
    Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
    Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
    Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
    Guerrero S; Libre C; Batisse J; Mercenne G; Richer D; Laumond G; Decoville T; Moog C; Marquet R; Paillart JC
    Sci Rep; 2016 Dec; 6():39507. PubMed ID: 27996044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
    Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
    Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GANP interacts with APOBEC3G and facilitates its encapsidation into the virions to reduce HIV-1 infectivity.
    Maeda K; Almofty SA; Singh SK; Eid MMA; Shimoda M; Ikeda T; Koito A; Pham P; Goodman MF; Sakaguchi N
    J Immunol; 2013 Dec; 191(12):6030-6039. PubMed ID: 24198285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA.
    Russell RA; Moore MD; Hu WS; Pathak VK
    Retrovirology; 2009 Feb; 6():16. PubMed ID: 19216784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
    Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
    J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
    Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
    mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
    Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
    J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3G inhibits elongation of HIV-1 reverse transcripts.
    Bishop KN; Verma M; Kim EY; Wolinsky SM; Malim MH
    PLoS Pathog; 2008 Dec; 4(12):e1000231. PubMed ID: 19057663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
    Hosseini I; Mac Gabhann F
    PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
    Feng Y; Love RP; Chelico L
    J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
    Mbisa JL; Barr R; Thomas JA; Vandegraaff N; Dorweiler IJ; Svarovskaia ES; Brown WL; Mansky LM; Gorelick RJ; Harris RS; Engelman A; Pathak VK
    J Virol; 2007 Jul; 81(13):7099-110. PubMed ID: 17428871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.
    Cadena C; Stavrou S; Manzoni T; Iyer SS; Bibollet-Ruche F; Zhang W; Hahn BH; Browne EP; Ross SR
    Retrovirology; 2016 Jun; 13(1):45. PubMed ID: 27363431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
    Martin KL; Johnson M; D'Aquila RT
    J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.